ICL's $350M EBITDA Reset: Underappreciated Turnaround or Expensive Promise?

ICL's cost reset is credible, but the earnings proof still has to show up

ICL has outlined a cost transformation program targeting more than $350 million in annual EBITDA improvements by 2028, and the timing matters because reported earnings must catch up before second-half performance is tested by higher sulfur prices, foreign exchange pressures, and weakness in key markets like Brazil.

The operating momentum is visible. In Q2, ICL reported sales of $2.1 billion, up 17% year over year, and adjusted EBITDA of $448 million, up 28%. Even after the recent rally, shares still sit approximately 30% below their 52-week high. The investment question is whether the market will pay for a turnaround before the next few quarters fully confirm it.

Bulls can point to real operating leverage. Management delivered strong Q2 results while also laying out a reset aimed at more than $350 million in annual EBITDA improvements by 2028.

Bears are right to focus on the next hurdle. Q2 was achieved despite higher raw material costs and currency fluctuations, and management warned that higher sulfur prices, foreign exchange pressures, and weakness in key markets like Brazil could weigh on second-half performance.

The real question is whether savings improve business mix, not just the cost base

ICL already gave investors a reason to look beyond a simple margin squeeze. In Q1, sales of $2.0 billion increased 14%, while operating income rose to $235 million and adjusted EBITDA reached $412 million, alongside lifted full-year EBITDA guidance. Profitability grew faster than revenue, which is the kind of spread investors want to see in a business trying to move away from commodity-style valuation logic.

ICL is more than a fertilizer cyclical

ICL is a leading global specialty minerals company operating across phosphate solutions, potash, industrial products and growing solutions. That means the $350 million target should not be treated as a pure overhead-cutting exercise. The better version of the story is one where efficiency gains support a higher-value mix, especially in specialty crop nutrition and specialty food solutions.

Where the $350 million is supposed to come from

Management is presenting a strategic reorganization beginning in 2027 that is aimed at more than $350 million in annual EBITDA improvements by 2028. The exact breakdown is not fully detailed in the supplied material, but the likely drivers include:

• operating efficiencies tied to the 2027-start reorganization
• better capital allocation as ICL narrows focus away from lithium iron phosphate battery projects and back toward core specialty chemicals and agricultural solutions

That portfolio reset matters. If savings are paired with a stronger specialty mix, the target becomes more than a cost-cutting headline.

Valuation now does most of the decision-making

The operating story no longer needs much convincing. The next issue is whether ICL deserves a specialty premium at today's valuation.

Pricing power is the key test

The growth spread matters. In Q1, sales of $2.0 billion increased 14% while operating income was $235 million, up 27%. In Q2, sales of $2.1 billion grew 17% and adjusted EBITDA of $448 million rose 28%. That consistency gives management credibility.

The valuation story is less one-sided. ICL traded at 24.51x P/E on March 31 earlier this year and was at 14.00x P/E as of June 2. That move lower suggests some optimism has already been removed. If the market starts pricing ICL again as a higher-quality specialty platform, multiple expansion could resume. If it keeps treating the company like a cyclical minerals producer, upside will depend much more on steady execution than on narrative.

What would confirm or break the thesis

The story is now moving from credibility to proof.

Three proof points to watch

1. Reported follow-through. The market needs the next few quarters to show that the recent strength was not a one-off beat. ICL still has to prove it can execute through higher raw material costs and negative foreign exchange effects.

2. Mix, not just margin. Investors should watch whether ICL keeps executing on specialty crop nutrition and specialty food solutions. The goal is to keep growth leaning toward the higher-value end of phosphate solutions, industrial products and growing solutions.

3. Early evidence before 2027. The strategic reorganization is important, but the near-term edge comes from showing early savings and better mix now, rather than relying on future reorganization headlines.

What would weaken the case

If the second half weakens while management still points to higher sulfur prices, foreign exchange pressures, and weakness in key markets like Brazil, the rerating thesis becomes much harder to defend.

For now, ICL looks more like a turnaround with a credible setup than a plain cyclical-provided the savings start showing up in reported results before 2027 reorganization talking points do most of the work.